Harnessing dendritic cell diversity in cancer immunotherapy

Research output: Contribution to journalReview ArticleResearchpeer-review

1 Citation (Scopus)


Dendritic cells (DCs) are ubiquitous immune cells endowed with a unique capacity to initiate antigen-specific immunity and tolerance. Owing to their unique functional attributes, DCs have long been considered ideal candidates for the induction of effective antitumour responses. At the forefront of the cancer-immunity cycle, attempts to harness DC natural adjuvant properties in the clinic have resulted so far in suboptimal antitumour responses. A better understanding of the heterogeneity of the DC network and its dynamics within the tumour microenvironment will provide a blueprint to fully capitalise on their functional properties to achieve more effective antitumour responses. In this review, we will briefly summarise the origin and heterogeneity of the DC network, their roles in shaping antitumour immunity and in modulating the response to immune checkpoint blockade therapies.

Original languageEnglish
Article number102341
Number of pages13
JournalCurrent Opinion in Immunology
Publication statusPublished - Jun 2023

Cite this